Metastasis of cancer is the process by which the primary tumor spreads from the original site to other parts of the body. Palliative care is the most common treatment option available for patients with metastatic cancer, but most patients eventually succumb to the disease due to the lack of therapeutics that can specifically target disseminated tumors [1].

Available targeted therapies for colorectal cancer (CRC) are limited. Immunotherapy offers new options for cancer treatment, but most of CRC are refractory to current immune checkpoint blockade, which indicates the possible presence of yet uncharacterized immune-suppressive mechanisms. Herein we report that high levels of Dickkopf-related protein 2 (DKK2) are expressed in human CRC tumors, and the DKK2 blockade caused stronger activation of tumor-infiltrating CD8+ T cells in ex vivo culture. A correlation of high DKK2 expression 

Intrahepatic cholangiocarcinoma (ICC), the second most frequent primary liver tumor, is a highly metastatic malignancy and often leads to disaster outcome in majority of patients, bringing significant challenges in the medical field [1].

Evolution of our thinking and design of cancer therapeutics has gone through a tortuous path in the last eighty or so years, since the first patient was treated with a chemical agent. Introduction of nitrogen mustard in the treatment of cancer in 1940’s was based on a serendipitous finding and observation during the second world war.

Gastric or gastroesophageal junction (GEJ) adenocarcinoma remains a fatal condition worldwide, ranking fifth in prevalence and fourth in mortality globally [1]. The treatment of advanced gastric cancer is currently stratified based on MSI (Microsatellite Instability) status and HER2 status.